A new conjugate vaccine for typhoid fever, known as Bharat Biotech’s Typbar-TCV, has been certified for use by the World Health Organisation (WHO). The new typhoid conjugate vaccine is packaged to help curb the frequent use of antibiotics for treatment of presumed typhoid fever, thereby slowing the increase in antibiotic resistance in Salmonella Typhi. TCVs provide lasting immunity than older vaccines, while treatment of typhoid is attained with fewer doses, and can be given to young children through routine childhood immunization programs. Prequalification of the vaccine by WHO connotes that the vaccine meets acceptable standards of quality, safety, and efficacy. Global estimates of the typhoid burden range between 11 and 20 million cases and between about 128 000 and 161 000 typhoid deaths annually.

Source: Nigerian Tribune January 04, 2018 18:45 UTC